TNFRSF8 and Hodgkins lymphoma: With the arrival of newer therapies such as BV, CPI, and CD30 directed chimeric antigen receptor T‐cell therapy (CD30.CAR‐T), the sequencing of therapies in R/R HL is under constant evolution, and therefore, appropriate timing of allo‐HCT is not well established.